Vaccine Response Impaired Clinical Trial
Official title:
Immune-Related Trafficking and Signaling in Human Skin Associated With Low-Power, Infrared Laser Treatment
The purpose of this is that the researcher can use low power Near Infrared laser treatment non-painful and non-damaging dose to changes the skin properties.The researcher can prove that signaling and a significant increase in the number of skin cells in skin tissue exposed to the laser can improve the human skin immune system to help improve human body response to vaccines.
The researcher can use low power laser light one-minute exposures delivered to the skin at non-painful and non-damaging dose. The resulted in significant immunologic changes in the skin that included up-regulation of specific skin tissue and skin genes and the activation and mobilization of specific skin cells. In the first part of the study, the researcher will make a determination of the laser irradiance that will be tolerated. The highest irradiance the subject tolerates for 1 minute will be identified as that subject's maximum tolerable irradiance. After all subjects are tested, researcher will select the highest irradiance that was tolerated and use this in the second phase of the study. Approximately 24 hours after the first test exposures, each subject will receive a one minute laser treatment at the maximum tolerable irradiance. Four hours later, two skin biopsies will be collected from laser treated site a untreated. One tissue sample will be test at UC Irvine Dept. of Dermatopathology to evaluate microscopic skin changes, one skin sample will be delivered to Massachusetts General Hospital to evaluate RNA and protein expression. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05060991 -
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
|
Phase 4 | |
| Active, not recruiting |
NCT01446978 -
Three Doses of Hepatitis A Vaccine in Patients With Immunomodulating Drugs
|
Phase 2 | |
| Completed |
NCT03855176 -
Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients
|
Phase 4 | |
| Not yet recruiting |
NCT05923970 -
Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
|
||
| Recruiting |
NCT05019248 -
Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
|
||
| Completed |
NCT03467074 -
Role of Interferon-λ and Vaccine Response
|
||
| Completed |
NCT05124509 -
Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant
|
||
| Completed |
NCT05791851 -
Heplisav-B Revaccination for Hepatitis B Vaccine Nonresponders
|
||
| Completed |
NCT05030974 -
RECOVAC Repeated Vaccination Study
|
Phase 4 | |
| Completed |
NCT03930017 -
Pregnancy, Arsenic and Immune Response
|
||
| Completed |
NCT05116748 -
COVID19 Vaccine in SOT Adult Recipients
|
||
| Recruiting |
NCT06148025 -
Antibiotics and Vaccine Immune Responses Study
|
Phase 4 | |
| Completed |
NCT03368495 -
Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines
|
Phase 4 | |
| Completed |
NCT04059991 -
Antibodies in Repeated Influenza Vaccination (ARIVA) Study
|
||
| Completed |
NCT04915820 -
Iron and COVID-19 Vaccine Response
|
N/A | |
| Completed |
NCT04912661 -
Iron and Vaccine Response
|
N/A | |
| Completed |
NCT04885907 -
Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients
|
Phase 4 | |
| Completed |
NCT03588013 -
Study of Environmental Enteropathy and Malnutrition in Pakistan
|
N/A | |
| Completed |
NCT04936997 -
Immune Response to the COVID-19 Vaccine
|
Early Phase 1 | |
| Completed |
NCT03996538 -
Vaccination Efficacy With Metformin in Older Adults
|
Phase 1 |